Scholarlink

Background <p>Malaria still poses a significant burden on global health, with millions of cases reported annually and rising resistance to current treatments, emphasizing the need for new therapeutic strategies. Fosmidomycin, initially recognized for its antibacterial properties, has emerged as a promising candidate in the fight against malaria.</p> Methods <p>In this study, a sensitive and robust LC–MS/MS method for quantifying fosmidomycin in human and rat plasma was developed and validated. Plasma samples were prepared using a simple protein precipitation method with 10% trichloroacetic acid (TCA). The assay featured a rapid run time of 5&#xa0;min, and validation was performed according to the European Medicines Agency's guidelines.</p> Results <p>The method validation confirmed its selectivity, linearity, accuracy, precision, and stability. Notably, the calibration range was established from 0.25 to 15&#xa0;mg/L, demonstrating improvements over previous methodologies with lower limits of quantification of 0.5–1.0&#xa0;mg/L. Using the developed LC–MS/MS method, plasma samples were analysed from a clinical trial conducted in Gabon, as well as from a pharmacokinetic study involving male Wistar rats, revealing viable pharmacokinetic profiles for fosmidomycin.</p> Conclusions <p>These findings confirm the utility of the developed analytical method for supporting the clinical development of fosmidomycin as a potential therapy for malaria.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development and application of an LC–MS/MS method for quantification of fosmidomycin in human and rat plasma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月25日

查看全文
  • Christoph Pfaffendorf,
  • Keanu D. Sackmann,
  • Johannes Mischlinger,
  • Jean Claude Dejon-Agobé,
  • Oumou Maïga-Ascofaré,
  • Ebenezer Ahenkan,
  • Ayôla Akim Adegnika,
  • Michael Ramharter,
  • Philipp Uhl,
  • Gert Fricker,
  • Sebastian G. Wicha

摘要

Background

Malaria still poses a significant burden on global health, with millions of cases reported annually and rising resistance to current treatments, emphasizing the need for new therapeutic strategies. Fosmidomycin, initially recognized for its antibacterial properties, has emerged as a promising candidate in the fight against malaria.

Methods

In this study, a sensitive and robust LC–MS/MS method for quantifying fosmidomycin in human and rat plasma was developed and validated. Plasma samples were prepared using a simple protein precipitation method with 10% trichloroacetic acid (TCA). The assay featured a rapid run time of 5 min, and validation was performed according to the European Medicines Agency's guidelines.

Results

The method validation confirmed its selectivity, linearity, accuracy, precision, and stability. Notably, the calibration range was established from 0.25 to 15 mg/L, demonstrating improvements over previous methodologies with lower limits of quantification of 0.5–1.0 mg/L. Using the developed LC–MS/MS method, plasma samples were analysed from a clinical trial conducted in Gabon, as well as from a pharmacokinetic study involving male Wistar rats, revealing viable pharmacokinetic profiles for fosmidomycin.

Conclusions

These findings confirm the utility of the developed analytical method for supporting the clinical development of fosmidomycin as a potential therapy for malaria.